Methylene blue increases systemic vascular resistance in human septic shock. Preliminary observations.

Schneider F, Lutun P, Hasselmann M, Stoclet JC, Tempé JD

Intensive care medicine1 Jan 1992Cited by 69 (Europe PMC)

PMID1527264DOI10.1007/bf01706481PepBankPUB-01527264

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanCase report or seriesEfficacy outcome
In patients with hyperdynamic septic shock, methylene blue increased low vascular resistance.
In plain wordsMethylene blue increased blood vessel resistance compared with before treatment in patients with septic shock.
Peptide
Methylene blue
Outcome
IncreaseVascular resistance
Study
n = 2
Comparator
Before methylene blue
Outcome group
Vascular function · Cardiovascular
Studied dose
2 mg.kg-1 · intravenousAs given in this study (human).
Source sentences
Summary
MB injection augmented the low vascular resistance, mean arterial pressure and induced a slight decrease of cardiac index, without any change of heart rate and pulmonary artery wedge pressure.
1 context sentence(design, population, supporting numbers)
Summary · context
We report the hemodynamic improvements induced by intravenous methylene blue (MB), a guanylate cyclase inhibitor, in 2 patients with hyperdynamic septic shock treated with norepinephrine (NE) infusion, mechanical ventilation and hemodialysis.
Report a problemFND-0152726401
02HumanCase report or seriesEfficacy outcome
In patients with hyperdynamic septic shock, methylene blue increased mean arterial pressure.
In plain wordsMethylene blue increased mean blood pressure compared with before treatment in patients with septic shock.
Peptide
Methylene blue
Outcome
IncreaseMean arterial pressure
Study
n = 2
Comparator
Before methylene blue
Outcome group
Blood pressure · Cardiovascular
Studied dose
2 mg.kg-1 · intravenousAs given in this study (human).
Source sentences
Summary
MB injection augmented the low vascular resistance, mean arterial pressure and induced a slight decrease of cardiac index, without any change of heart rate and pulmonary artery wedge pressure.
1 context sentence(design, population, supporting numbers)
Summary · context
We report the hemodynamic improvements induced by intravenous methylene blue (MB), a guanylate cyclase inhibitor, in 2 patients with hyperdynamic septic shock treated with norepinephrine (NE) infusion, mechanical ventilation and hemodialysis.
Report a problemFND-0152726402
03HumanCase report or seriesEfficacy outcome
In patients with hyperdynamic septic shock, methylene blue slightly decreased cardiac index.
In plain wordsMethylene blue slightly reduced heart pumping output relative to body size compared with before treatment in patients with septic shock.
Peptide
Methylene blue
Outcome
DecreaseCardiac index
Study
n = 2
Comparator
Before methylene blue
Outcome group
Heart function · Cardiovascular
Studied dose
2 mg.kg-1 · intravenousAs given in this study (human).
Source sentences
Summary
MB injection augmented the low vascular resistance, mean arterial pressure and induced a slight decrease of cardiac index, without any change of heart rate and pulmonary artery wedge pressure.
1 context sentence(design, population, supporting numbers)
Summary · context
We report the hemodynamic improvements induced by intravenous methylene blue (MB), a guanylate cyclase inhibitor, in 2 patients with hyperdynamic septic shock treated with norepinephrine (NE) infusion, mechanical ventilation and hemodialysis.
Report a problemFND-0152726403
04HumanCase report or seriesEfficacy outcome
In patients with hyperdynamic septic shock, heart rate did not change after methylene blue.
In plain wordsHeart rate did not change compared with before methylene blue in patients with septic shock.
Peptide
Methylene blue
Outcome
No significant changeHeart rate
Study
n = 2
Comparator
Before methylene blue
Outcome group
Heart function · Cardiovascular
Studied dose
2 mg.kg-1 · intravenousAs given in this study (human).
Source sentences
Summary
MB injection augmented the low vascular resistance, mean arterial pressure and induced a slight decrease of cardiac index, without any change of heart rate and pulmonary artery wedge pressure.
1 context sentence(design, population, supporting numbers)
Summary · context
We report the hemodynamic improvements induced by intravenous methylene blue (MB), a guanylate cyclase inhibitor, in 2 patients with hyperdynamic septic shock treated with norepinephrine (NE) infusion, mechanical ventilation and hemodialysis.
Report a problemFND-0152726404
05HumanCase report or seriesEfficacy outcome
In patients with hyperdynamic septic shock, pulmonary artery wedge pressure did not change after methylene blue.
In plain wordsPulmonary artery wedge pressure did not change compared with before methylene blue in patients with septic shock.
Peptide
Methylene blue
Outcome
No significant changePulmonary artery wedge pressure
Study
n = 2
Comparator
Before methylene blue
Outcome group
Heart function · Cardiovascular
Studied dose
2 mg.kg-1 · intravenousAs given in this study (human).
Source sentences
Summary
MB injection augmented the low vascular resistance, mean arterial pressure and induced a slight decrease of cardiac index, without any change of heart rate and pulmonary artery wedge pressure.
1 context sentence(design, population, supporting numbers)
Summary · context
We report the hemodynamic improvements induced by intravenous methylene blue (MB), a guanylate cyclase inhibitor, in 2 patients with hyperdynamic septic shock treated with norepinephrine (NE) infusion, mechanical ventilation and hemodialysis.
Report a problemFND-0152726405
06HumanCase report or seriesMechanism
In patients with hyperdynamic septic shock, plasma cyclic GMP levels decreased after methylene blue.
In plain wordsPlasma cyclic GMP levels decreased compared with before methylene blue in patients with septic shock.
Peptide
Methylene blue
Outcome
DecreasePlasma cyclic GMP
Study
n = 2
Comparator
Before methylene blue
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
2 mg.kg-1 · intravenousAs given in this study (human).
Source sentences
Summary
Plasma cyclic GMP levels decreased without a significant change of atrial natriuretic factor levels.
1 context sentence(design, population, supporting numbers)
Summary · context
We report the hemodynamic improvements induced by intravenous methylene blue (MB), a guanylate cyclase inhibitor, in 2 patients with hyperdynamic septic shock treated with norepinephrine (NE) infusion, mechanical ventilation and hemodialysis.
Report a problemFND-0152726406
07HumanCase report or seriesMechanism
In patients with hyperdynamic septic shock, atrial natriuretic factor levels did not change significantly after methylene blue.
In plain wordsAtrial natriuretic factor levels did not change significantly compared with before methylene blue in patients with septic shock.
Peptide
Methylene blue
Outcome
No significant changeAtrial natriuretic factor levels
Study
n = 2
Comparator
Before methylene blue
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
2 mg.kg-1 · intravenousAs given in this study (human).
Source sentences
Summary
Plasma cyclic GMP levels decreased without a significant change of atrial natriuretic factor levels.
1 context sentence(design, population, supporting numbers)
Summary · context
We report the hemodynamic improvements induced by intravenous methylene blue (MB), a guanylate cyclase inhibitor, in 2 patients with hyperdynamic septic shock treated with norepinephrine (NE) infusion, mechanical ventilation and hemodialysis.
Report a problemFND-0152726407
08HumanCase report or seriesEfficacy outcome
In patients with hyperdynamic septic shock, methylene blue produced a longer lasting improvement in circulatory failure.
In plain wordsMethylene blue gave a longer lasting improvement in circulatory failure in patients with septic shock.
Peptide
Methylene blue
Outcome
DecreaseCirculatory failure
Study
n = 2
Outcome group
Heart function · Cardiovascular
Studied dose
2 mg.kg-1 · intravenousAs given in this study (human).
Source sentences
Summary
MB (2 mg.kg-1) induced a longer lasting improvement of circulatory failure without deleterious side effects, but did not prevent the occurrence of delayed multiorgan failure or subsequent death.
1 context sentence(design, population, supporting numbers)
Summary · context
We report the hemodynamic improvements induced by intravenous methylene blue (MB), a guanylate cyclase inhibitor, in 2 patients with hyperdynamic septic shock treated with norepinephrine (NE) infusion, mechanical ventilation and hemodialysis.
Report a problemFND-0152726408
09HumanCase report or seriesSafety outcome
In patients with hyperdynamic septic shock, methylene blue produced no deleterious side effects.
In plain wordsNo harmful side effects were reported after methylene blue in patients with septic shock.
Peptide
Methylene blue
Outcome
Not applicableDeleterious side effects
Study
n = 2
Outcome group
Adverse events · Whole body
Studied dose
2 mg.kg-1 · intravenousAs given in this study (human).
Source sentences
Summary
MB (2 mg.kg-1) induced a longer lasting improvement of circulatory failure without deleterious side effects, but did not prevent the occurrence of delayed multiorgan failure or subsequent death.
1 context sentence(design, population, supporting numbers)
Summary · context
We report the hemodynamic improvements induced by intravenous methylene blue (MB), a guanylate cyclase inhibitor, in 2 patients with hyperdynamic septic shock treated with norepinephrine (NE) infusion, mechanical ventilation and hemodialysis.
Report a problemFND-0152726409
10HumanCase report or seriesSafety outcome
In patients with hyperdynamic septic shock, methylene blue did not prevent delayed multiorgan failure.
In plain wordsDelayed failure of multiple organs occurred despite methylene blue treatment in patients with septic shock.
Peptide
Methylene blue
Outcome
Not applicableDelayed multiorgan failure
Study
n = 2
Outcome group
Adverse events · Whole body
Studied dose
2 mg.kg-1 · intravenousAs given in this study (human).
Source sentences
Summary
MB (2 mg.kg-1) induced a longer lasting improvement of circulatory failure without deleterious side effects, but did not prevent the occurrence of delayed multiorgan failure or subsequent death.
1 context sentence(design, population, supporting numbers)
Summary · context
We report the hemodynamic improvements induced by intravenous methylene blue (MB), a guanylate cyclase inhibitor, in 2 patients with hyperdynamic septic shock treated with norepinephrine (NE) infusion, mechanical ventilation and hemodialysis.
Report a problemFND-0152726410
11HumanCase report or seriesSafety outcome
In patients with hyperdynamic septic shock, methylene blue did not prevent subsequent death.
In plain wordsDeath occurred despite methylene blue treatment in patients with septic shock.
Peptide
Methylene blue
Outcome
Not applicableSubsequent death
Study
n = 2
Outcome group
Mortality · Whole body
Studied dose
2 mg.kg-1 · intravenousAs given in this study (human).
Source sentences
Summary
MB (2 mg.kg-1) induced a longer lasting improvement of circulatory failure without deleterious side effects, but did not prevent the occurrence of delayed multiorgan failure or subsequent death.
1 context sentence(design, population, supporting numbers)
Summary · context
We report the hemodynamic improvements induced by intravenous methylene blue (MB), a guanylate cyclase inhibitor, in 2 patients with hyperdynamic septic shock treated with norepinephrine (NE) infusion, mechanical ventilation and hemodialysis.
Report a problemFND-0152726411

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.